QIAGEN partners to develop predictive tests in oncology

Yesterday, we announced that QIAGEN was entering into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.

See the full press release here.

We will demonstrate our Sample to Insight solutions for molecular diagnostic and research applications in oncology at Booth 18031 at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting on June 3-7, 2016, in Chicago. Click here for more information on QIAGEN’s presence at ASCO.

Frances Slater

Frances Slater, PhD, is a Senior Technical and Marketing Writer for Global MDx Marketing at QIAGEN. She trained as a molecular biologist at King's College London before moving into marketing communications for the pharmaceutical and diagnostics industries. She is passionate about communicating the power and value of molecular technologies for research and healthcare.

Your email address will not be published. Required fields are marked *

More Articles Like This

Multi-center study shows QIAGEN’s ipsogen JAK2 MutaQuant Kit is robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation

A network study of multiple laboratories finds the ipsogen JAK2 MutaQuant Kit to be robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation. This study sets the basis for the standardization of molecular techniques for JAK2 V617F determination. The JAK2 V617F mutation is an important diagnostic biomarker for Philadelphia (Ph)- negative myeloproliferative... Read article →

A call for new ALK fusion screening methods

ALK gene rearrangements have been described in 3–5% of lung adenocarcinomas (ADC), and the presence of dysregulated ALK has been described in at least 18 cancer types (reviewed in 1). Since lung cancer is a common type of cancer, an estimated 70,000 cases of non-small cell lung cancer (NSCLC) which have ALK genomic alterations  occur... Read article →